Drivers of absolute systemic bioavailability after oral pulmonary inhalation in humans. 2021

Astrid Bacle, and Guillaume Bouzillé, and Arnaud Bruyère, and Marc Cuggia, and Olivier Fardel, and Pascal Le Corre
Pôle Pharmacie, Service Hospitalo-Universitaire de Pharmacie, CHU de Rennes, 35033 Rennes, France; Laboratoire de Biopharmacie et Pharmacie Clinique, Faculté de Pharmacie, Université de Rennes 1, 35043 Rennes, France; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France.

There are few studies in humans dealing with the relationship between physico-chemical properties of drugs and their systemic bioavailability after administration via oral inhalation route (Fpulm). Getting further insight in the determinants of Fpulm after oral pulmonary inhalation could be of value for drugs considered for a systemic delivery as a result of poor oral bioavailability, as well as for drugs considered for a local delivery to anticipate their undesirable systemic effects. To better delineate the parameters influencing the systemic delivery after oral pulmonary inhalation in humans, we studied the influence of physico-chemical and permeability properties obtained in silico on the rate and extent of Fpulm in a series of 77 compounds with or without marketing approval for pulmonary delivery, and intended either for local or for systemic delivery. Principal component analysis (PCA) showed mainly that Fpulm was positively correlated with Papp and negatively correlated with %TPSA, without a significant influence of solubility and ionization fraction, and no apparent link with lipophilicity and drug size parameters. As a result of the small sample set, the performance of the different models as predictive of Fpulm were quite average with random forest algorithm displaying the best performance. As a whole, the different models captured between 50 and 60% of the variability with a prediction error of less than 20%. Tmax data suggested a significant positive influence of lipophilicity on absorption rate while charge apparently had no influence. A significant linear relationship between Cmax and dose (R2 = "0.79) highlighted that Cmax was primarily dependent on dose and absorption rate and could be used to estimate Cmax in humans for new inhaled drugs.

UI MeSH Term Description Entries
D008168 Lung Either of the pair of organs occupying the cavity of the thorax that effect the aeration of the blood. Lungs
D010539 Permeability Property of membranes and other structures to permit passage of light, heat, gases, liquids, metabolites, and mineral ions. Permeabilities
D004364 Pharmaceutical Preparations Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. Drug,Drugs,Pharmaceutical,Pharmaceutical Preparation,Pharmaceutical Product,Pharmaceutic Preparations,Pharmaceutical Products,Pharmaceuticals,Preparations, Pharmaceutical,Preparation, Pharmaceutical,Preparations, Pharmaceutic,Product, Pharmaceutical,Products, Pharmaceutical
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000280 Administration, Inhalation The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract. Drug Administration, Inhalation,Drug Administration, Respiratory,Drug Aerosol Therapy,Inhalation Drug Administration,Inhalation of Drugs,Respiratory Drug Administration,Aerosol Drug Therapy,Aerosol Therapy, Drug,Drug Therapy, Aerosol,Inhalation Administration,Administration, Inhalation Drug,Administration, Respiratory Drug,Therapy, Aerosol Drug,Therapy, Drug Aerosol
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D012995 Solubility The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed) Solubilities

Related Publications

Astrid Bacle, and Guillaume Bouzillé, and Arnaud Bruyère, and Marc Cuggia, and Olivier Fardel, and Pascal Le Corre
May 1992, Antimicrobial agents and chemotherapy,
Astrid Bacle, and Guillaume Bouzillé, and Arnaud Bruyère, and Marc Cuggia, and Olivier Fardel, and Pascal Le Corre
July 1987, International journal of clinical pharmacology, therapy, and toxicology,
Astrid Bacle, and Guillaume Bouzillé, and Arnaud Bruyère, and Marc Cuggia, and Olivier Fardel, and Pascal Le Corre
September 1992, Journal of clinical pharmacology,
Astrid Bacle, and Guillaume Bouzillé, and Arnaud Bruyère, and Marc Cuggia, and Olivier Fardel, and Pascal Le Corre
April 1997, The Annals of pharmacotherapy,
Astrid Bacle, and Guillaume Bouzillé, and Arnaud Bruyère, and Marc Cuggia, and Olivier Fardel, and Pascal Le Corre
January 1994, Drug metabolism and drug interactions,
Astrid Bacle, and Guillaume Bouzillé, and Arnaud Bruyère, and Marc Cuggia, and Olivier Fardel, and Pascal Le Corre
March 1992, Antimicrobial agents and chemotherapy,
Astrid Bacle, and Guillaume Bouzillé, and Arnaud Bruyère, and Marc Cuggia, and Olivier Fardel, and Pascal Le Corre
October 2023, Clinical pharmacology in drug development,
Astrid Bacle, and Guillaume Bouzillé, and Arnaud Bruyère, and Marc Cuggia, and Olivier Fardel, and Pascal Le Corre
September 1986, Antimicrobial agents and chemotherapy,
Astrid Bacle, and Guillaume Bouzillé, and Arnaud Bruyère, and Marc Cuggia, and Olivier Fardel, and Pascal Le Corre
May 1977, American journal of hospital pharmacy,
Astrid Bacle, and Guillaume Bouzillé, and Arnaud Bruyère, and Marc Cuggia, and Olivier Fardel, and Pascal Le Corre
April 1984, Klinische Wochenschrift,
Copied contents to your clipboard!